World Journal of Urology · 2025 · 11 citations · 12 references
MedicineOncologyGenitourinary OncologyMetastasisRenal PathologyKidney CancerMalignant NeoplasmsRenal Cell CarcinomaRenal NeoplasmsTumor ClassificationTumor GradingKaplan-meier Survival EstimatesPrognostic ClassificationPrognostic PredictionPrognostic VariablesRecurrence-free SurvivalSarcoma GradingSarcomatoid Renal Cell CarcinomaSarcomatoid Renal Neoplasms
PURPOSE: Sarcomatoid dedifferentiation represents one of the most aggressive features of clear cell renal cell carcinoma (ccRCC). In this study we evaluated whether grade 4-ccRCC subclassification based on the intratumoral abundance of sarcomatoid features could have a prognostic impact. METHODS: A cohort of 212 patients with localized or locally advanced sarcomatoid ccRCC was identified. This population was stratified according to abundance of sarcomatoid features in low-sarcomatoid (LS = < 20% sarcomatoid component; n = 117) and high-sarcomatoid (HS = ≥ 20% sarcomatoid component; n = 95). Estimates of cancer-specific survival (CSS) and recurrence-free survival (RFS) were calculated according to the Kaplan-Meier method and compared with the log-rank test. Multivariable analysis was performed using the Cox proportional hazards regression model to identify the most significant variables for predicting CSS and RFS. RESULTS: Kaplan-Meier survival curves stratified by abundance of sarcomatoid component, showed that CSS and RFS were significantly decreased in patients with sarcomatoid component ≥ 20% (both P < 0.0001). At multivariable analysis by Cox regression modeling, the abundance of sarcomatoid component was an independent adverse prognostic factor for CSS (P < 0.0001) and RFS (P < 0.0001). CONCLUSION: ccRCC Subclassification based on the abundance of intratumoral sarcomatoid component has a clinical significance. Our study showed that ccRCC subclassification into HS versus LS groups had a prognostic impact in terms of CSS and RFS in non-metastatic ccRCC.
12
Rebecca L. Siegel, Angela N. Giaquinto, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2024 · 9K citations · Full text
Medicine, Oncology, Cancer Control +16
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Robert J. Motzer, Romain Banchereau, Habib Hamidi et al. · Cancer Cell · 2020 · 561 citations · Full text
Medicine, Cancer Biology, Oncology +16
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Ziad Bakouny, David A. Braun, Sachet A. Shukla et al. · Nature Communications · 2021 · 168 citations · Full text
Medicine, Cancer Biology, Oncology +17